A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
Public ClinicalTrials.gov record NCT03742102. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase IB/II, 2-stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) + Paclitaxel and Durvalumab (MEDI4736) in Combination With Novel Oncology Therapies With or Without Paclitaxel for First-line Metastatic Triple Negative Breast Cancer
Study identification
- NCT ID
- NCT03742102
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- AstraZeneca
- Industry
- Enrollment
- 243 participants
Conditions and interventions
Conditions
Interventions
- Capivasertib Drug
- Datopotamab deruxtecan Drug
- Durvalumab Drug
- Oleclumab Drug
- Paclitaxel Drug
- Trastuzumab deruxtecan Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 130 Years
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 20, 2018
- Primary completion
- Nov 28, 2024
- Completion
- Feb 25, 2027
- Last update posted
- Apr 23, 2026
2018 – 2027
United States locations
- U.S. sites
- 8
- U.S. states
- 7
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Tucson | Arizona | 85715 | — |
| Research Site | Columbia | Maryland | 21044 | — |
| Research Site | Boston | Massachusetts | 02114 | — |
| Research Site | Boston | Massachusetts | 02215 | — |
| Research Site | Grand Rapids | Michigan | 49503 | — |
| Research Site | St Louis | Missouri | 63110 | — |
| Research Site | Dallas | Texas | 75246 | — |
| Research Site | Williamsburg | Virginia | 23188 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 24 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03742102, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 23, 2026 · Synced May 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03742102 live on ClinicalTrials.gov.